- Home
- IKT vs MHLD Comparison
IKT vs MHLD Comparison
Compare IKT & MHLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- MHLD
- Stock Information
- Founded
- IKT 2008
- MHLD 2007
- Country
- IKT United States
- MHLD Bermuda
- Employees
- IKT N/A
- MHLD N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- MHLD Property-Casualty Insurers
- Sector
- IKT Health Care
- MHLD Finance
- Exchange
- IKT Nasdaq
- MHLD Nasdaq
- Market Cap
- IKT 159.2M
- MHLD 159.6M
- IPO Year
- IKT 2020
- MHLD 2008
- Fundamental
- Price
- IKT $2.31
- MHLD $1.72
- Analyst Decision
- IKT Strong Buy
- MHLD
- Analyst Count
- IKT 2
- MHLD 0
- Target Price
- IKT $6.50
- MHLD N/A
- AVG Volume (30 Days)
- IKT 310.9K
- MHLD 88.4K
- Earning Date
- IKT 11-14-2024
- MHLD 11-12-2024
- Dividend Yield
- IKT N/A
- MHLD N/A
- EPS Growth
- IKT N/A
- MHLD N/A
- EPS
- IKT N/A
- MHLD N/A
- Revenue
- IKT $1.00
- MHLD $89,074,000.00
- Revenue This Year
- IKT N/A
- MHLD N/A
- Revenue Next Year
- IKT N/A
- MHLD N/A
- P/E Ratio
- IKT N/A
- MHLD N/A
- Revenue Growth
- IKT N/A
- MHLD 20.80
- 52 Week Low
- IKT $0.85
- MHLD $1.19
- 52 Week High
- IKT $3.82
- MHLD $2.55
- Technical
- Relative Strength Index (RSI)
- IKT 52.09
- MHLD 51.18
- Support Level
- IKT $1.75
- MHLD $1.57
- Resistance Level
- IKT $2.10
- MHLD $1.75
- Average True Range (ATR)
- IKT 0.33
- MHLD 0.10
- MACD
- IKT -0.10
- MHLD -0.01
- Stochastic Oscillator
- IKT 28.87
- MHLD 41.03
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About MHLD Maiden Holdings Ltd.
Maiden Holdings Ltd provides reinsurance products and services to regional and specialty property and casualty insurers. The company operates in two segments: AmTrust Reinsurance and Diversified Reinsurance. The AmTrust Reinsurance segment provides products that cover workers' compensation, commercial package, commercial auto, and extended warranty. The Diversified Reinsurance segment provides small and midsize regional and specialty insurers with reinsurance capital products. Its revenues also include fee income earned from both its GLS business and IIS business as well as income generated from its investment portfolio.